Lisa Baumann Kreuziger
The purpose of this study is to compare the benefits, harms, and burdens of two different approaches to anticoagulation therapy in patients with cancer: -anticoagulation therapy with a low molecular weight heparin (LMWH) alone or followed by warfarin (the usual approach, described above). versus -anticoagulation therapy with a direct oral anticoagulant (DOAC) (called the study approach in this form). All of the medications used in this study have already been FDA-approved to treat blood clots. Therapy with a DOAC is already FDA-approved for use as anticoagulation therapy, but DOACs have not been studied extensively in patients with cancer. This study will allow the researchers to gather information about whether anticoagulation therapy with a LMWH alone or followed by warfarin is better, the same, or worse than anticoagulation therapy with a DOAC in patients with cancer.
Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer (CANVAS)
OPEN TO ACCRUAL